Healthcare & Life Sciences Tech Active Acquirer Report Q2 2019

doctor with tablet technology
Share This Post

The healthcare and life sciences tech industry has experienced some geopolitical uncertainties and market volatility in recent years. But, despite these challenges, there is still a high level of optimism among investors in the sector.

According to Deloitte’s 2019 Global Life Sciences Outlook, healthcare spending across 60 countries is expected to increase by 5.4% for the 2018-2022 period. This compares to just 2.9% for the 2013-2017 period. This is good news for investors.

Our Healthcare & Life Sciences Tech Active Acquirer Report explores recent acquirer trends, strategic insights, key investment drivers, and transaction information for the most recent or relevant acquisitions in addition to an extensive list of active buyers to help you stay ahead in this dynamic and constantly evolving industry. 

Are you interested in finding out about who is actively acquiring in the health care and life sciences tech industry? In this report, we highlight two large strategic acquirers and a private equity firm who are active in the space.

Click below to download the full report

healthcare life sciences report cover

Objective Capital Partners has decades of experience and our tenacious advocacy for our clients has allowed us to create and maintain relationships with active acquirers and investors in our industries of focus. Whether preparing for sale or strategizing for future exit options, knowing the active acquirers and investors within your industry niche is an important factor in achieving your transaction goals. 

If you are interested in learning more about the trends and insights in the health care & life sciences tech industry, or if you would like to discuss your own acquisition goals, contact us at (858) 208-3442 or [email protected].

About the Author:

Trever Acers headshotTrever Acers

Managing Director

20+ Years of Experience

[email protected]


Objective Capital Partners is a leading investment banking advisory firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies with annual revenues up to $250MM. Services include sale transactions, partnering/ licensing, equity and debt capital raises, valuation and comprehensive advisory services. The firm uses a proprietary process to work to achieve maximum company valuation, premium pricing, and high client satisfaction rates post-sale. The firm’s industry expertise is focused on 5 verticals including healthcare, life sciences, business services, technology, and consumer products. Additional information on Objective Capital Partners is available at

This article is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities.

More Posts